Nazan Günel

1.1k total citations
60 papers, 836 citations indexed

About

Nazan Günel is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Nazan Günel has authored 60 papers receiving a total of 836 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 18 papers in Molecular Biology and 12 papers in Cancer Research. Recurrent topics in Nazan Günel's work include Cancer Treatment and Pharmacology (9 papers), Inflammasome and immune disorders (6 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Nazan Günel is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Inflammasome and immune disorders (6 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Nazan Günel collaborates with scholars based in Türkiye, United States and Sweden. Nazan Günel's co-authors include Uğur Çoşkun, Banu Sancak, Ayşe Dursun, Deniz Yamaç, Ahmet Demirkazık, Dìlek Dìnçol, Fikri İçlı, Erhan Onuk, Nalân Akyürek and Füsun Baloş Törüner and has published in prestigious journals such as Cancer, European Journal of Cancer and British Journal of Haematology.

In The Last Decade

Nazan Günel

56 papers receiving 817 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nazan Günel Türkiye 17 332 303 129 126 123 60 836
Rajendra Ramsamooj United States 14 231 0.7× 256 0.8× 112 0.9× 152 1.2× 182 1.5× 32 938
Diana Stempak Canada 16 254 0.8× 380 1.3× 174 1.3× 202 1.6× 126 1.0× 22 975
Sophie Broutin France 16 311 0.9× 213 0.7× 123 1.0× 96 0.8× 109 0.9× 48 787
Sonja Mandl–Weber Germany 16 225 0.7× 511 1.7× 89 0.7× 97 0.8× 114 0.9× 26 921
John Frye United States 10 286 0.9× 222 0.7× 91 0.7× 172 1.4× 86 0.7× 24 754
Evangelos Messaris United States 15 249 0.8× 261 0.9× 65 0.5× 107 0.8× 250 2.0× 36 875
Marisa Cañadas‐Garre Spain 19 256 0.8× 435 1.4× 192 1.5× 175 1.4× 73 0.6× 44 1.0k
James Raschko United States 20 416 1.3× 212 0.7× 157 1.2× 179 1.4× 223 1.8× 50 1.1k
Balraj Mittal India 20 306 0.9× 284 0.9× 132 1.0× 185 1.5× 241 2.0× 43 837
Yasuji Yoshikawa Japan 17 330 1.0× 522 1.7× 125 1.0× 260 2.1× 171 1.4× 51 1.1k

Countries citing papers authored by Nazan Günel

Since Specialization
Citations

This map shows the geographic impact of Nazan Günel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nazan Günel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nazan Günel more than expected).

Fields of papers citing papers by Nazan Günel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nazan Günel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nazan Günel. The network helps show where Nazan Günel may publish in the future.

Co-authorship network of co-authors of Nazan Günel

This figure shows the co-authorship network connecting the top 25 collaborators of Nazan Günel. A scholar is included among the top collaborators of Nazan Günel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nazan Günel. Nazan Günel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Erdal, Mehmet Okan, et al.. (2025). Promising pioneer study on identification of lung cancer cells using DNA-based Schottky diodes. Sensors and Actuators A Physical. 387. 116407–116407. 1 indexed citations
3.
Üner, Aytuğ, et al.. (2023). Greater financial toxicity correlates with increased psychological distress and lower quality of life among Turkish cancer patients. Supportive Care in Cancer. 31(2). 137–137. 9 indexed citations
4.
Öksüzoğlu, Berna, Nuriye Özdemir, Aytuğ Üner, et al.. (2022). Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 40(11). 494.e1–494.e10. 18 indexed citations
5.
İlhan, Ayşegül, Deniz Can Güven, Gökhan Uçar, et al.. (2021). Thirty-day Mortality Rates After Immunotherapy Initiation. Immunotherapy. 13(17). 1419–1426. 2 indexed citations
6.
Günel, Nazan, et al.. (2013). Longterm followup of a hip joint osteoblastoma after intralesional curettage and cement packing: a case report. Acta Orthopaedica et Traumatologica Turcica. 47(3). 218–222. 2 indexed citations
7.
Yaman, Emel, Süleyman Buyukberber, Aytuğ Üner, et al.. (2008). Temozolomide in Newly Diagnosed Malignant Gliomas: Administered Concomitantly with Radiotherapy, and Thereafter as Consolidation Treatment. Onkologie. 31(6). 309–313. 7 indexed citations
8.
Çoşkun, Uğur, et al.. (2004). Pulmonary resection in a metastatic breast cancer patient with fourteen years survival: a case report. American Journal of Case Reports. 5. 12–13. 1 indexed citations
9.
Çoşkun, Uğur, et al.. (2004). Gemcitabine induced pulmonary injury. American Journal of Case Reports. 5. 178–179. 2 indexed citations
10.
Çoşkun, Uğur, et al.. (2004). Kikuchi-Fujimoto Hastalığı. Turkiye Klinikleri Tip Bilimleri Dergisi. 24(1). 106–108.
11.
Sancak, Banu, Uğur Çoşkun, Nazan Günel, et al.. (2004). No association between serum levels of insulin‐like growth factor‐I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery. Internal Medicine Journal. 34(6). 310–315. 12 indexed citations
12.
Demirer, Taner, Meltem Aylı, Yavuz Selim Genç, et al.. (2003). High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation. Bone Marrow Transplantation. 31(9). 755–761. 5 indexed citations
13.
Demirer, Taner, Meltem Aylı, Rauf Haznedar, et al.. (2002). Influence of post‐transplant recombinant human granulocyte colony‐stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. British Journal of Haematology. 118(4). 1104–1111. 18 indexed citations
14.
15.
Günel, Nazan, et al.. (2002). Prognostic Importance of Tumor Angiogenesis in Breast Carcinoma with Adjuvant Chemotherapy. Pathology - Research and Practice. 198(1). 7–12. 12 indexed citations
16.
Akyürek, Nalân, Gülen Akyol, Ayşe Dursun, Deniz Yamaç, & Nazan Günel. (2002). Expression of MUC1 and MUC2 Mucins in Gastric Carcinomas: Their Relationship with Clinicopathologic Parameters and Prognosis. Pathology - Research and Practice. 198(10). 665–674. 37 indexed citations
17.
Dursun, Ayşe, Nalân Akyürek, Nazan Günel, & Deniz Yamaç. (2002). Prognostic implication of nm23-H1 expression in colorectal carcinomas. Pathology. 34(5). 427–432. 21 indexed citations
18.
İçlı, Fikri, et al.. (1993). Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 72(2). 587–593. 107 indexed citations
19.
Dìnçol, Dìlek, et al.. (1992). Primary gastrointestinal lymphomas in Turkey: A retrospective analysis of clinical features and results of treatment. Journal of Surgical Oncology. 51(4). 270–273. 15 indexed citations
20.
İçlı, Fikri, et al.. (1991). Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin. Journal of Surgical Oncology. 48(3). 199–201. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rajendra Ramsamooj Breakdown of academic impact, for papers by Diana Stempak Breakdown of academic impact, for papers by Sophie Broutin Breakdown of academic impact, for papers by Sonja Mandl–Weber Breakdown of academic impact, for papers by John Frye Breakdown of academic impact, for papers by Evangelos Messaris Breakdown of academic impact, for papers by Marisa Cañadas‐Garre Breakdown of academic impact, for papers by James Raschko Breakdown of academic impact, for papers by Balraj Mittal Breakdown of academic impact, for papers by Yasuji Yoshikawa
Rankless by CCL
2026